FDA Approves Pimjetmi for Tenosynovial Giant Cell Tumor
Merck KGaA (MKGAF) and its partner Abbisko Therapeutics have received FDA approval for Pimjetmi, a once-daily oral therapy. The treatment is indicated for adults suffering from tenosynovial giant cell tumor (TGCT), which is a rare non-cancerous condition. Pimjetmi functions as a colony-stimulating factor-1 receptor (CSF-1R) inhibitor. This approval marks a significant regulatory milestone for the collaborative development efforts between Merck KGaA and Abbisko Therapeutics in addressing orphan disease markets.
Topics: drug launch FDA approval oncology/biotech rare disease